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Abstract
The peptide repertoire that is presented by the set of HLA class I molecules of an individual is formed by the different
players of the antigen processing pathway and the stringent binding environment of the HLA class I molecules. Peptide
elution studies have shown that only a subset of the human proteome is sampled by the antigen processing machinery and
represented on the cell surface. In our study, we quantified the role of each factor relevant in shaping the HLA class I
peptide repertoire by combining peptide elution data, in silico predictions of antigen processing and presentation, and data
on gene expression and protein abundance. Our results indicate that gene expression level, protein abundance, and rate of
potential binding peptides per protein have a clear impact on sampling probability. Furthermore, once a protein is available
for the antigen processing machinery in sufficient amounts, C-terminal processing efficiency and binding affinity to the HLA
class I molecule determine the identity of the presented peptides. Having studied the impact of each of these factors
separately, we subsequently combined all factors in a logistic regression model in order to quantify their relative impact.
This model demonstrated the superiority of protein abundance over gene expression level in predicting sampling
probability. Being able to discriminate between sampled and non-sampled proteins to a significant degree, our approach
can potentially be used to predict the sampling probability of self proteins and of pathogen-derived proteins, which is of
importance for the identification of autoimmune antigens and vaccination targets.
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Introduction
Major histocompatibility complex (MHC) class I molecules play
a crucial role in the adaptive immune response of higher
vertebrates. These molecules, in humans referred to as human
leukocyte antigen (HLA) class I molecules, bind peptides derived
from endogenous proteins of host or, in the case of infected cells, of
pathogen origin and present them to circulating CD8+ T
lymphocytes and natural killer (NK) cells. The presentation of
self peptides by an individual’s HLA class I molecules has an
impact on positive and negative selection of CD8+ T lymphocytes
in the thymus [1,2], maintenance of naive T cells in the periphery
[3,4], and inhibition of NK cells through recognition of self
peptides in the context of HLA class I molecules by killer cell
immunoglobulin-like receptors (KIR) [5].
Generally, HLA class I ligands are derived from intracellular
proteins, which are degraded by the proteasome into peptide
fragments. These peptides are then translocated by the transporter
associated with antigen processing (TAP) into the lumen of the
endoplasmic reticulum (ER), where they may be loaded onto an
HLA molecule if the peptide sequence fits the HLA molecule’s
binding preference. The C-terminus of an HLA ligand is assumed
to be mainly determined by the proteasome (even though recently
a carboxypeptidase has been found to contribute to C-terminal
editing [6]), whereas the N-terminus may be trimmed by cytosolic
and endoplasmic aminopeptidases after proteasomal cleavage [7].
Finally, the HLA-peptide complexes are transported to the cell
surface for presentation to CD8+ T cells and NK cells.
Several studies analyzed peptide data sets obtained by peptide
elution from specific cell lines and peptide sequencing by mass
spectrometry to characterize the HLA peptide repertoire
[8,9,10,11]. Most of these studies focused on characterizing the
function and subcellular localization of source proteins and
suggested that HLA class I presented peptides are sampled from
functionally and compartmentally diverse proteins, with a
functional bias towards RNA-binding proteins [8]. In human
cells, a weak correlation has been found between the abundance of
HLA class I ligands presented and the corresponding mRNA levels
[10,11], whereas peptides eluted from murine thymocytes were
preferentially derived from highly abundant mRNAs [12].
Here, we take a different angle to the question of what fraction
of the human proteome is represented on the cell surface. We
studied two large HLA ligand data sets obtained by peptide elution
[13,14] with the aim to quantify the role of several factors shaping
the peptide repertoire of HLA class I molecules. We show that the
gene expression level, protein abundance, rate of potential binding
peptides in a protein and the processing quality of these peptides
all contribute to which proteins are sampled and which peptides
are chosen to be presented on the cell surface. Having studied the
impact of each of these factors separately, we subsequently
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quantify their relative impact. This model can potentially be used
to predict the sampling probability of self proteins and of
pathogen-derived proteins.
Results
Elution data sets and procedure to determine HLA
binders
We studied two different peptide elution data sets. One large set,
which we will call the Johnson data, comprises 4717 human
peptides and 105 vaccinia peptides eluted from vaccinia infected
cells [13]. A second set of eluted peptides, the Ben Dror data,
comprises 569 human peptides eluted from soluble HLA-B*27:05
(see Materials and Methods for details) [14]. By mapping each
eluted peptide to the human proteome, we were able to uniquely
identify the source protein for 90% (4243 of 4717) of the Johnson
data and 81.9% (466 of 569) of the Ben Dror data. Peptides that
mapped to several human proteins (about 9%) or for which no
source protein could be identified (only 0.4–1.1%) were excluded
from further analysis.
The cell line used for the generation of the Johnson data was
homozygous for HLA-A*02:01, B*15:01 and C*03. In order to
assess which of these three HLA molecules each of the reported
peptides was eluted from, we employed NetMHC 3.2 [15,16], a
tool for HLA-peptide binding prediction. This tool is applicable
for peptides of 8 to 13 amino acids in length [15]. Of all eluted
peptides of appropriate length and that could be mapped uniquely
to a human source protein (4113 of 4243 peptides), we were able
to assign 86.4% (3552 of 4113) to either being eluted from A*02:01
or B*15:01. The remaining 561 peptides could potentially have
been eluted from C*03. Binding predictions, however, suggested
C*03 binding only for a minor fraction of these (28% for all
peptide lengths and 37% for 9mers), and therefore we decided to
exclude these peptides from further analysis. Surprisingly, we
identified twice as many potential B*15:01 binders as A*02:01
binders, originating from a larger number of source proteins
(Fig. 1). This observation is in agreement with the estimation given
by the original study [13], in which the assignment to the
restricting HLA molecule was solely determined based on the C-
terminal residues of the eluted peptides. Likewise, among the
vaccinia-derived peptides, a larger number of peptides (1.5-fold)
were eluted from B*15:01 than from A*02:01, mapping to a larger
number of vaccinia proteins, even though in this case the
difference was less pronounced (Fig. 1).
Of the 569 eluted peptides in the Ben Dror data, 466 peptides
(81.9%) mapped uniquely to 396 human source proteins. Among
these peptides, 420 (90.1%) were predicted to bind to HLA-
B*27:05, the soluble HLA molecule expressed by the cells studied.
For all three HLA alleles studied, the majority of sampled proteins
were represented by only a single peptide: 86.9% (457 of 526) of
the proteins sampled by A*02:01, 76.1% (981 of 1289) of the ones
Figure 1. Composition of the Johnson data. The pie charts depict the fractions of eluted peptides that were predicted to bind to HLA-A*02:01,
B*15:01, both, or neither of the two alleles. Predictions were only performed for peptides of 8–13 amino acids in length (n=4113 for human-derived
peptides, n=103 for vaccinia). The Venn diagrams indicate the number of source proteins these peptides originated from.
doi:10.1371/journal.pcbi.1002517.g001
Author Summary
HLA class I molecules are expressed on the cell surface of
almost all cells of the human body in complex with short
fragments (peptides) of cytosolic proteins, thereby provid-
ing a snapshot of the intracellular state of a cell to
circulating CD8+ T cells. Several processes are involved in
shaping the peptide ligand repertoire of an HLA class I
molecule, which generally represents only a small fraction
of the proteins available in the cytosol. In our work we
addressed protein sampling by HLA class I molecules to
answer two questions: 1) Which proteins are sampled by
the antigen processing pathway and why, and 2) which
peptides of a given protein are picked to represent the
source protein on the cell surface? To this end we
quantified the contribution of each process involved in
peptide processing and presentation individually and
combined them into a logistic regression model. This
simple model enabled us to predict the sampling
probability of self proteins and may aid in the identifica-
tion of autoimmune antigens.
Proteome Sampling by HLA Class I
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sampled by B*27:05 gave rise to only one eluted peptide.
In total, the two elution data sets had 160 source proteins in
common. GO-term enrichment analysis (see Materials and
Methods) revealed that for this set of proteins biological processes
relating to the cell cycle and its regulation as well as nucleic acid
metabolic processes were overrepresented.
Eluted peptides are characterized by higher binding
affinity and more efficient processing
The observation that a protein is represented on the cell surface
by one or more peptides allows the assumption that the protein
must have been available in sufficient amounts or must have been
present at an accessible subcellular location to be available for the
antigen processing machinery. What factors then determine which
of the potential HLA binders of a given protein will be found on
the cell surface?
In order to characterize the obtained peptide set, we employed
prediction methods for HLA binding and antigen processing (see
Materials and Methods). For the identified source proteins, we
predicted all potential (9mer) binders to HLA-A*02:01, B*15:01,
and B*27:05 and compared the predicted binding affinity of the
eluted peptides (which form a subset of all potential binders) with
the predicted binders from the same source protein that were not
found in the elution. To ensure an unbiased comparison, the set of
eluted peptides was limited to 9mers that were predicted to bind to
the respective HLA molecule. We found that eluted peptides bind
their HLA molecule with a significantly higher (predicted) binding
affinity than other potential binders (Fig. 2A).
However, not all predicted high-affinity binders were found in
the elution. In order to investigate whether this observation may
be due to inefficient processing of these peptides, we predicted the
probability of C-terminal processing (using NetChop [17]) for all
eluted peptides and all predicted binders that were not found in
the elution data set. Based on these predictions, the set of eluted
peptides is indeed more likely to arise from antigen processing as
compared to the set of predicted binders (Fig. 2B). Possibly due to
co-evolution between HLA class I molecules and the immuno-
proteasome [18], predicted binding affinity and C-terminal
processing probability show a weak (but significant) correlation
(Kendall’s tau=20.065, p-value,0.0001). Therefore, we investi-
gated the effect of processing without the influence of HLA
binding by comparing the eluted peptide set to an affinity-matched
subset of predicted binders to ensure that eluted and predicted
peptides show the same distribution of binding affinities (Fig. S1A).
Also for this subset of predicted binders we observed a significantly
lower C-terminal processing probability (Fig. S1B). NetChop was
trained on the C-termini of known HLA ligands and therefore
predicts the combined effect of proteasome and TAP. Investigating
the impact of these two processes separately (by employing
prediction methods that are part of mhc-pathway [19,20])
suggested that the C-termini of eluted peptides are more likely
to be produced by the immunoproteasome and that these peptides
are more efficiently transported by TAP (Fig. S2).
For non-self peptides, we observed the same characteristics.
Eluted peptides that originated from vaccinia proteins showed a
significantly higher binding affinity to the respective HLA allotype
than other potential binders derived from the same set of proteins
(Fig. S3A). A difference in predicted C-terminal processing
probability between eluted and other peptides was, however, only
found for A*02:01-binding vaccinia peptides (Fig. S3B). Interest-
ingly, we did not observe a difference in predicted HLA binding
affinity between the eluted peptides that originate from human
proteins and vaccinia proteins (results not shown). This is in line
with an earlier study, which showed that the HLA alleles analyzed
here do not show a preference for presentation of non-self over self
peptides, while others, foremost HLA-A alleles, do [21,22].
Protein abundance impacts protein sampling rate
After having investigated what factors determine which peptides
of a given protein are chosen to be presented, we turned to
investigate which features of a protein impact protein sampling
itself. In other words, why are some proteins sampled while others
are not? Previous studies have shown that proteins giving rise to
HLA ligands are foremost intracellular, distributed over various
intracellular compartments with a slight bias towards the cytosol
[8,23]. Predicting the subcellular localization of each of the
sampled proteins in the two data sets of our study, we found
similar results: Overall, the distribution of cellular compartments
for the sets of source proteins significantly differed from the
distribution for the complete human proteome (Fig. S4), and
specifically, extracellular proteins were significantly underrepre-
sented in both elution data sets (p,1e-09, Chi-squared test), while
proteins resident in the cytosol were overrepresented (p,2e-05). In
addition, we tested several protein characteristics for their ability
to discriminate source proteins from proteins that were not
sampled by the antigen processing pathway. For all three HLA
allotypes studied, source proteins are longer, more abundant, and
the corresponding genes are more highly expressed (Fig. 3). These
factors, however, are not independent. As expected, gene
expression level and protein abundance are moderately correlated
(Spearman’s rho=0.3, p-value,2e-16). Additionally, we noticed
that protein length and abundance are inversely correlated to each
other, with shorter proteins being more abundant (rho=20.41, p-
value,2e-16). Since we found that sampled proteins were longer
but at the same time more abundant, correcting for protein length
(by choosing a random subset of non-sampled proteins with the
same length distribution as the set of sampled proteins) enhanced
the difference in protein abundance even (Fig. S5). In addition,
proteins that were sampled in both elution studies (n=160) were
found to be more abundant than source proteins that emerged
only in one of the data sets (median abundance=17.54 ppm (parts
per million, see Materials and Methods) compared to 3.15 ppm,
p=1e-10). Moreover, we found a significantly higher rate of
predicted binders (in the following referred to as the ‘‘predicted hit
rate’’) in sampled proteins, most pronounced for A*02:01-specific
source proteins (median hit rate=0.3 for sampled proteins vs.
0.025 for non-sampled proteins, p=7e-14). Interestingly, within
the same cell line, proteins that were sampled only by B*15:01
show a significantly lower predicted hit rate for A*02:01 than
proteins that have been sampled by A*02:01 (median hit
rate=0.030 vs. 0.026, p=7e-13), further emphasizing that the
relative number of potential binding peptides does have an
influence on sampling probability.
We do not have abundance data for vaccinia proteins available,
but Assarsson et al. [24] measured vaccinia gene expression at
several time points after infection. For each time point, we found a
positive correlation between the gene expression level and the
sampling frequency of the proteins when comparing single-
sampled and multiple-sampled source proteins with those that
did not give rise to eluted peptides (Fig. S6). Additionally, as for
human proteins, sampled vaccinia proteins are longer than the
remaining vaccinia proteins (p,0.01, data not shown).
Putting it all together - prediction of protein sampling
Overall, all tested factors - protein length, gene expression level,
protein abundance, and predicted hit rate - show differences
between the set of sampled proteins and the proteins that were not
Proteome Sampling by HLA Class I
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to determine which combination of factors best describes the data,
we performed a multiple logistic regression analysis. Starting from
a maximal model including all factors as explanatory variables, we
obtained a minimal model by iterative exclusion of non-significant
factors. Before running the regression, we first randomly picked a
subset of non-sampled proteins to form a ‘‘negative’’ set of equal
size as the positive set of sampled proteins. This balanced set of
negative and positive data points was then used to perform a
logistic regression and performance analysis (see Materials and
Methods), which was repeated 100 times with different random
negative subsets. The performance was measured as the Spearman
correlation coefficient between the known sampling status (i.e., a
binary value) and the predicted sampling probability. For all three
HLA allotypes, a regression model combining protein abundance,
protein length and predicted hit rate showed the best performance
(the best examples are given in Fig. 4A–C). Since we found that
eluted peptides are more efficiently processed than other HLA-
binding peptides, we tested whether we could improve the model
by filtering the set of predicted binders for processing efficiency.
For all three HLA allotypes, this filtering step improved the
prediction performance only to a minor extent (results not shown).
As gene expression and protein abundance are moderately
correlated, we tested which of these two factors would carry more
information for predicting protein sampling. We found that
protein abundance clearly outcompetes gene expression (Fig. 5).
Among the three HLA allotypes, the prediction performance of
the B*27:05 model was best (Fig. 4C), with an average AUC (area
Figure 2. Eluted peptides show higher binding affinity to HLA and more efficient C-terminal processing. The boxplots compare eluted
9mer peptides and predicted binders from the same set of source proteins in terms of (A) predicted binding affinity to A*02:01, B*15:01, and B*27:05,
respectively, and (B) predicted C-terminal processing probability. For the matter of correctness, we removed eluted peptides from the data set that
had also been part of the NetChop training set (n=15).
doi:10.1371/journal.pcbi.1002517.g002
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0.74 compared to 0.70 for A*02:01 and 0.68 for B*15:01 (Fig. 4D).
Overall, the resulting logistic regression models were able to
discriminate between sampled and non-sampled proteins to a
significant degree (Fig. 4A–C).
Discussion
Only a small fraction of the human proteome is sampled by the
class I antigen processing pathway and presented on HLA class I
molecules. Previously it was suggested that the cellular localization
of a protein and its function play a role in this sampling process
[8,23]. Here we show that other protein characteristics like protein
length, abundance, and rate of predicted binders also largely
influence the sampling probability of a protein and thereby shape
the peptide repertoire of an HLA class I molecule.
We analyzed two large peptide elution datasets; one derived
from a vaccinia virus infected cell line, and one obtained from cells
transfected with a gene encoding a soluble HLA class I molecule.
Identification of the source protein of each peptide showed that, in
spite of the huge difference in proteome size between human and
vaccinia virus, a similar fraction of either proteome (10–12% of all
proteins) was sampled by the antigen processing pathway. We
characterized the set of eluted peptides in terms of antigen
processing and presentation and observed a significantly higher
binding affinity to the respective HLA molecule and more efficient
processing for the eluted peptides than for other potential binders
derived from the same set of source proteins. The predicted
median affinity of eluted peptides was 14 nM IC50 for A*02:01,
65 nM IC50 for B*15:01, and 107 nM IC50 for B*27:05. These
values are much lower than the 500 nM, which are often used as a
threshold to discriminate HLA-binding peptides from non-binders
[26]. This observation could reflect that high-affinity binders are
preferentially loaded onto the HLA molecule among others with
the help of the ER resident chaperone tapasin [27,28], or that they
have a longer ‘‘life span’’ on the cell surface because they form a
more stable complex with the HLA molecule, which increases
their chance of being eluted (even though this is rather related to
the off-rate of a peptide than to its affinity). Especially for the
elution studies involving soluble HLA molecules, it is not
surprising to identify foremost high-affinity binders after the long
affinity purification process [14]. A higher binding affinity of
eluted peptides has also been found for mouse MHC class I
molecules [12]. If high-affinity peptides are able to outcompete
lower affinity-peptides in binding to the HLA, this may result in a
higher copy number of these peptides on the cell surface which in
turn increases their chance to be detected by mass spectrometry.
The nature of the data sets we analyzed does not allow us to study
this because we do not have abundance data on the peptides.
Instead we merely know whether a peptide was present in the
eluate or not.
To our surprise, most proteins were represented by only a single
peptide in the elution data sets we studied. This is in line with the
observation by Hickman et al. [8] who found only 9 of 189 source
proteins (4.8%) to be represented by more than one peptide.
For the prediction of C-terminal processing, we employed a
method that has been trained on the C-termini of known HLA
Figure 3. Protein length, gene expression level, and protein
abundance impact protein sampling probability. The boxplots
compare sampled and non-sampled human proteins in terms of (A)
protein length, (B) gene expression level, and (C) protein abundance.
The difference in protein counts between plots is due to lack of (gene
expression or protein abundance) data for some of the proteins.
doi:10.1371/journal.pcbi.1002517.g003
Proteome Sampling by HLA Class I
PLoS Computational Biology | www.ploscompbiol.org 5 May 2012 | Volume 8 | Issue 5 | e1002517ligands [17]. Initially intended as a predictor of proteasomal
cleavage, the method automatically accounts for the contribution
of other potential peptidases that are able to further process the
carboxy terminus of proteasome products, as for example the
carboxypeptidase ACE [6]. It does, however, not account for the
activity of aminopeptidases in the cytosol and ER, which may
further trim the amino termini of peptides. There is some evidence
for the existence of N-terminal processing motives, which differ in
specificity between cytosol and ER [29,30]. However, the lack of
appropriate prediction methods prevented us from assessing the
effect of N-terminal trimming of peptides in our analysis.
For the data sets we studied, we observed that (i) source proteins
are longer and more abundant than non-source proteins, (ii) the
corresponding genes show higher expression levels, and (iii) source
proteins show a higher rate of predicted binders than proteins that
were not sampled. We combined these factors in a logistic
regression model and conclude that prediction of protein sampling
probability is possible to some degree. The best model made use of
protein length, abundance, and predicted hit rate to predict the
sampling probability of a protein. Fortier et al. [12] observed that
MHC-presented peptides are preferentially derived from highly
abundant mRNAs. Our analysis confirmed the impact of gene
expression reported earlier by Fortier et al., but in addition, our
results suggest that protein abundance carries more information
for the prediction of protein sampling than transcript levels do.
It has been argued that antigen processing should be correlated
with protein turnover rather than cellular abundance of proteins
[10]. In addition, a recent study suggested that the pioneer round
of mRNA translation, which serves as a ‘‘proof-reading’’ step
during mRNA maturation, might be a major source of HLA
ligands [31]. We believe that the model presented in this paper will
improve considerably when more data is available describing the
specificity and kinetics of peptide generation via these processes.
Finally, another source of antigenic peptides are so-called defective
ribosomal products (DRiPs), which are truncated and/or mis-
folded polypeptides that are directly targeted to proteasomal
degradation [32,33]. The DRiP hypothesis suggests that the set of
MHC-presented peptides reflects recent protein synthesis rather
than the protein content of the cell, which should manifest itself in
our analysis as a higher correlation with gene expression level than
with protein abundance. Even though this is not what we see, the
fact that HLA ligands are preferentially derived from long proteins
is in accordance with the DRiP hypothesis, because the chance of
incorporating errors and of misfolding increases with protein
length.
A limitation of our analysis is the presumably high noise in the
protein abundance and gene expression data. The abundance data
was derived through meta-analysis from a multitude of different
tissue types, even though there is considerable variation of protein
Figure 4. The regression model is able to distinguish sampled
from non-sampled proteins. (A–C) Predicted sampling probability
for A*02:01, B*15:01, and B*27:05 (best examples of 100 cross-validation
runs per allele; solid line: sampled proteins; dashed line: non-sampled
proteins). The sampling probability is calculated as f(z)=e
z/(e
z+1) where
z=c+cab log10(ab)+cpl pl+chr hr with ab the protein abundance, pl the
protein length, hr the predicted hit rate, and (A) c=21.47, cab=0.49,
cpl=0.0009, chr=17.7, p-value=5e-15, (B) c=21.42, cab=0.46,
cpl=0.001, chr=16.5, p-value=1e-14, and (C) c=21.77, cab=1.15,
cpl=0.0005, chr=47.4, p-value=1e-10. (D) Receiver operating charac-
teristic (ROC) curve for A*02:01 (dashed), B*15:01 (solid), and B*27:05
(dash-dot) visualizing the performance of each of the regression models
as a mean over 100 runs. The dotted line represents the ROC curve for
random classification. Corresponding area under the curve (AUC): 0.70
for A*02:01, 0.68 for B*15:01, and 0.74 for B*27:05.
doi:10.1371/journal.pcbi.1002517.g004
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report, the abundance data set consists mainly of house-keeping
genes whose tissue-to-tissue expression variability is limited.
Ideally, the analysis presented here should be repeated on a data
set where mRNA levels, protein abundance, and HLA peptide
presentation are measured simultaneously for a single cell type or
tissue sample to minimize noise. All the more striking it is,
however, that we see a clear signal for both gene expression and
protein abundance in their impact on protein sampling in spite of
the noise introduced by averaging over cell types.
In conclusion, the results presented in this paper demonstrate
that protein characteristics such as gene expression level, protein
abundance, and the rate of HLA ligands determine which protein
will be sampled for antigen presentation. Moreover, our results
suggest that sampling prediction may be extended to the




Johnson et al. [13] performed peptide elution and mass-
spectrometry analysis of vaccinia virus infected Epstein-Barr
virus-transformed B-cells, homozygous for HLA-A*02:01,
B*15:01, and C*03 (for details see [13]). With a false positive
rate (FPR) of 5%, they identified 4717 unique human-derived
peptides and 119 vaccinia derived peptides.
Ben Dror et al. [14] eluted peptides from cultured cartilage cells
and HeLa cells transfected with a soluble form of HLA-B*27:05.
Based on several criteria to assess the confidence in identified
peptides, they categorized eluted peptides into three subsets:
certain (569 peptides), probable (582 peptides), and possible (116
peptides). As the certain peptide set corresponds to a FPR of 4.7%,
we limited our analysis to this data set. Of note, in the original
publication, peptides were selected as correct only if they
contained the amino acids arginine or glutamine at their second
position [14], which according to the authors (personal commu-
nication) was necessary in order to filter out peptides that were
eluted from other HLA allotypes expressed by the cell line (which
may become soluble due to cellular stress).
Identification of source proteins
We obtained the human proteome from Ensembl Genomes
(ftp.ensembl.org/pub/, release 56) and used this collection of
proteins to identify the source protein for each peptide in our
elution data sets. Source protein identification required identical
mapping of a peptide to the source protein sequence. Peptides that
could not be uniquely mapped to one single protein were omitted
from further analysis. In the case of several splice variants of the
same protein (i.e., the peptide matched to several protein
sequences which all originate from the same gene), the longest
splice variant was chosen for sequence analysis. Likewise, the
longest splice variant was chosen for the set of non-sampled
proteins. We were able to map 105 of the vaccinia peptides to the
Vaccinia Western Reserve proteome (GenBank identifier:
AY243312).
Abundance and gene expression data
We had abundance data available for 12,021 human proteins
[34]. The abundance is expressed in parts per million (ppm),
relative to the molecule counts of all other proteins in the
proteome. The measured abundance for different proteins spans
several orders of magnitude. The protein abundance data covers
1986 (78.4%) of the 2533 Johnson source proteins and 340 (85.8%)
of the 396 Ben Dror source proteins.
We used gene expression data from Juncker et al. [23], who
provide the median of normalized mRNA levels of haematopoietic
tissues originally obtained from the GNF gene expression database
[35]. Expression levels of vaccinia virus genes were obtained from
Assarsson et al. [24].
Prediction methods
Throughout the study we used the method NetMHC 3.2
[15,16] to predict peptide-binding to the HLA molecules A*02:01,
B*15:01, and B*27:05. Binding predictions for C*03 were done
using NetMHCpan 2.4 [36]. We define predicted binders as
peptides that have a predicted binding affinity of ,500 nM IC50
for a particular HLA molecule. For the Ben Dror data, where all
identified peptides were eluted from a known HLA molecule
(namely, HLA-B*27:05), this proved to be a suitable threshold,
predicting 89.6% (510 of 569) of the eluted peptides as binders.
Figure 5. Protein abundance carries more information for the prediction of sampling probability than gene expression level.
Boxplots of the Spearman correlation coefficients resulting from one hundred 56cross-validation runs for regression models that either include gene
expression data or protein abundance data.
doi:10.1371/journal.pcbi.1002517.g005
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prediction of C-terminal processing. Furthermore, we used weight
matrices provided by the mhc-pathway package [19,20] for the
prediction of cleavage probability by the immunoproteasome and
for TAP transport efficiency. We employed WoLF PSORT [38] to
predict subcellular localization of proteins and confirmed our
results by GO-term enrichment analysis using the Cytoscape [39]
plug-in Bingo [40].
Predicted hit rate
The predicted hit rate for a given protein is defined as the ratio of
the number of predicted binders for a particular HLA allotype to the
total number of unique 9mer peptides in this protein. Multiple
occurrences of the same peptide within one protein were counted as
a single occurrence, because they would also not be detected as
separatepeptidesintheelutionanalysis.Thehitrateiscalculatedper
HLA allele and hit rates may differ between alleles, because we use a
fixed affinity threshold of 500 nM IC50 to define binders (instead of
assigning a fixed fraction of peptides, e.g. top 1%, as binders). For
this reason we did not directly compare hit rates between alleles, but
instead performed separate analyses per HLA allele.
Statistical analysis
Two-sided Mann-Whitney tests, correlation tests, Chi-squared
tests, and logistic regression analysis were performed using R
(http://www.R-project.org). We used a generalized linear model
with a binomial response distribution and a logit function for data
transformation to model the impact of various factors on sampling
probability. All figures were produced using R.
Supporting Information
Figure S1 Eluted peptides show a significantly higher C-
terminal processing probability than other predicted binders. (A)
In order to normalize the peptide data sets for predicted binding
affinity, for each HLA allotype, we picked an affinity-matched
subset of predicted binders so that the range of predicted binding
affinities was the same as the range for eluted peptides. (B) After
normalizing for the binding affinity, eluted peptides still show a
significantly higher C-terminal processing probability.
(TIF)
Figure S2 Eluted peptides are more likely to be produced by the
immunoproteasome and are more efficiently transported by TAP.
The boxplots compare eluted 9mer peptides and predicted binders
from the same set of source proteins in terms of (A) predicted C-
terminal cleavage probability by the immunoproteasome and (B)
predicted TAP transport efficiency. Here, the eluted peptides are
compared to all predicted binders originating from the same set of
source proteins. Similar results are obtained when using an
affinity-matched subset of predicted binders (cf. Fig. S1).
(TIF)
Figure S3 Eluted vaccinia peptides show a significantly higher
(A) predicted binding affinity to A*02:01 and B*15:01, respective-
ly, and (B) predicted C-terminal processing probability (for
A*02:01-eluted peptides) than other predicted binders from the
same set of vaccinia proteins.
(TIF)
Figure S4 Distribution of predicted cellular compartments for
all human proteins and the source proteins identified for the
Johnson data and the Ben Dror data. Subcellular localization as given
by WoLF PSORT (nucl=nucleus, mito=mitochondria, extr=ex-
tracellular, ER=endoplasmic reticulum, cyto_nucl=cytosol and
nucleus, cyto=cytosol, plas=plasma membrane). Proteins target-
ed to the extracellular compartment were underrepresented with
6% for the Johnson and 8% for the Ben Dror data compared to 20%
among all human proteins (p,2e-16 and p=5e-10, respectively,
Chi-squared test), whereas cytosolic proteins were overrepresented
among the sampled proteins (27%–28% vs. 18%, p,2e-05). These
results were confirmed by a GO-term enrichment analysis
performed using the Cytoscape plug-in Bingo, which identified a
significant underrepresentation of GO-terms relating to the
plasma membrane (19% among sampled vs. 32% among all
human proteins) and the extracellular compartment (4.5% vs.
12.5%), while revealing an enrichment of intracellular proteins
(93% vs. 70%).
(TIF)
Figure S5 Comparison of sampled and non-sampled human
proteins in terms of protein abundance after normalization for
protein length. Normalization was achieved by choosing a random
subset of non-sampled proteins that show the same length
distribution as the set of sampled proteins.
(TIF)
Figure S6 The gene expression level of vaccinia genes is
correlated with the sampling state (none, one, or several peptides
found by elution). The gene expression level was measured at
indicated time points after infection by Assarsson et al. (2008).
(TIF)
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